Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The non-opioid nature of Journavx is expected to be a key differentiator in a market that is increasingly seeking alternatives to traditional opioid-based pain medications. Vertex’s pipeline ...

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

A decade from now, considering Vertex's pipeline, the company could potentially ... common problem that has limited treatment options: pain. Today's over-the-counter choices sometimes aren't ...

Pain is an area with limited treatment options ... Last year’s Alpine acquisition added povetacicept to Vertex’s pipeline, which Vertex believes has a “pipeline in a product” potential.

Vertex reported in December 2024 that the ... Latigo's funds will also support the rest of its pain pipeline, which includes another Nav1.8 inhibitor and an acid-sensing ion channel-targeting ...

The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these ...

transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational ...